MLYS

SEC source: 0001933414-25-000076 · wk-form4_1752613231.xml · derivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,880

Underlying: Common Stock · 6,349 shares

Expires 2032-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-25-000076 · wk-form4_1752613231.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,907

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.0700 to $14.7594. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

SEC source: 0001933414-25-000076 · wk-form4_1752613231.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,273

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

F2 · balance_after: This balance includes 1,273 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.

SEC source: 0001933414-25-000077 · wk-form4_1752613283.xml · nonDerivative · entry 1

Levy Adam Scott · CIK 0001693134 · CFO and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 206,612

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.3012 to $14.6546. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F3 · balance_after: This balance includes 2,030 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.

SEC source: 0001933414-25-000078 · wk-form4_1752613354.xml · nonDerivative · entry 1

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 846,405

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2024.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.30 to $14.73. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001933414-25-000067 · wk-form4_1750104191.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,651

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.370 to $14.835. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001933414-25-000067 · wk-form4_1750104191.xml · derivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 95,229

Underlying: Common Stock · 6,348 shares

Expires 2032-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

F3 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-25-000067 · wk-form4_1750104191.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 113,017

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

SEC source: 0001933414-25-000062 · wk-form4_1747350094.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,669

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.9100 to $15.7726. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001933414-25-000060 · wk-form4_1747184222.xml · derivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,577

Underlying: Common Stock · 6,349 shares

Expires 2032-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-25-000060 · wk-form4_1747184222.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 118,035

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

SEC source: 0001933414-25-000047 · wk-form4_1744763954.xml · derivative · entry 4

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 107,926

Underlying: Common Stock · 6,348 shares

Expires 2032-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

F3 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-25-000047 · wk-form4_1744763954.xml · nonDerivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 111,686

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

SEC source: 0001933414-25-000047 · wk-form4_1744763954.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,086

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.5382 to $13.8250. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001933414-25-000047 · wk-form4_1744763954.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 123,052

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

SEC source: 0001933414-25-000046 · wk-form4_1744763754.xml · nonDerivative · entry 1

Levy Adam Scott · CIK 0001693134 · CFO and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 215,340

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.78 to $12.35. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001933414-25-000044 · wk-form4_1744763608.xml · nonDerivative · entry 1

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 862,289

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2024.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.0200 to $12.4087. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001933414-25-000029 · wk-form4_1743716211.xml · derivative · entry 5

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 114,274

Underlying: Common Stock · 1,606 shares

Expires 2032-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-25-000029 · wk-form4_1743716211.xml · nonDerivative · entry 4

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,704

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

SEC source: 0001933414-25-000029 · wk-form4_1743716211.xml · nonDerivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 139,110

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.6434 to $16.2450. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

SEC source: 0001933414-25-000029 · wk-form4_1743716211.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 141,901

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.50 to $15.48. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001933414-25-000029 · wk-form4_1743716211.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 172,475

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

SEC source: 0001415889-25-008274 · form4-03182025_010312.xml · nonDerivative · entry 1

AKKARAJU SRINIVAS · CIK 0001253170 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Samsara BioCapital, L.P.

Disclosed balance after: 5,674,916

F1 · ownership.nature: Securities are directly held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-25-008257 · form4-03172025_110349.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director

RA Capital Healthcare Fund LP · CIK 0001315082 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director

Shah Rajeev M. · CIK 0001619841 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 4,280,051

F1 · ownership.nature: Held directly by the RA Capital Healthcare Fund, L.P. (the "Fund").

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001415889-25-008275 · form4-03182025_010343.xml · nonDerivative · entry 1

Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner

Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Samsara BioCapital, L.P.

Disclosed balance after: 5,674,916

F1 · ownership.nature: Securities are directly held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein.

SEC source: 0001933414-25-000052 · wk-form4_1745622111.xml · nonDerivative · entry 1

Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner

Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 8,903,838

F1 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, which is the general partner of Catalys Pacific Fund GP, LP. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001933414-25-000021 · wk-form4_1741900533.xml · derivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,880

Underlying: Common Stock · 6,349 shares

Expires 2032-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-25-000021 · wk-form4_1741900533.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,869

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-25-000015 · wk-form4_1740441536.xml · derivative · entry 1

Gold Alexander M · CIK 0002026429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,900

Underlying: Common Stock · 32,900 shares

Expires 2035-02-13

F1 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant.

SEC source: 0001933414-25-000013 · wk-form4_1740441514.xml · derivative · entry 1

Karydas Daphne · CIK 0001816952 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,900

Underlying: Common Stock · 32,900 shares

Expires 2035-02-13

F1 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant.

SEC source: 0001933414-25-000020 · wk-form4_1740441586.xml · derivative · entry 1

Levy Adam Scott · CIK 0001693134 · CFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2035-02-13

F1 · derivative.exercise_date: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month anniversary following the date of grant.

SEC source: 0001933414-25-000019 · wk-form4_1740441576.xml · derivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2035-02-13

F1 · derivative.exercise_date: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month anniversary following the date of grant.

SEC source: 0001933414-25-000018 · wk-form4_1740441567.xml · derivative · entry 1

AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner

Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,900

Underlying: Common Stock · 32,900 shares

Expires 2035-02-13

F1 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant.

SEC source: 0001933414-25-000012 · wk-form4_1740441504.xml · derivative · entry 1

SBLENDORIO GLENN · CIK 0001277478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,900

Underlying: Common Stock · 32,900 shares

Expires 2035-02-13

F1 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant.

SEC source: 0001415889-25-005380 · form4-02252025_020233.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director

RA Capital Healthcare Fund LP · CIK 0001315082 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director

Shah Rajeev M. · CIK 0001619841 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 32,900

Underlying: Common Stock · 32,900 shares

Expires 2035-02-13

F1 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F3 · ownership.nature: Derek DiRocco is a Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. DiRocco's arrangement with the Adviser, Dr. DiRocco holds the option for the benefit of the Fund and the Nexus Fund III. Dr. DiRocco is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

SEC source: 0001933414-25-000014 · wk-form4_1740441525.xml · derivative · entry 1

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 570,000

Underlying: Common Stock · 570,000 shares

Expires 2035-02-13

F1 · derivative.exercise_date: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month anniversary following the date of grant.

SEC source: 0001933414-25-000017 · wk-form4_1740441556.xml · derivative · entry 3

Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner

Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 32,900

Underlying: Common Stock · 32,900 shares

Expires 2035-02-13

F2 · kind: Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP.

F1 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant.

F3 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, which is the general partner of Catalys Pacific Fund GP, LP. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001933414-25-000017 · wk-form4_1740441556.xml · derivative · entry 2

Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner

Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,900 shares

Expires 2035-02-13

F2 · kind: Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP.

F1 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant.

SEC source: 0001933414-25-000017 · wk-form4_1740441556.xml · derivative · entry 1

Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner

Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,900

Underlying: Common Stock · 32,900 shares

Expires 2035-02-13

F1 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant.

SEC source: 0001933414-25-000016 · wk-form4_1740441546.xml · derivative · entry 1

DiRocco Derek · CIK 0001792061 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,900

Underlying: Common Stock · 32,900 shares

Expires 2035-02-13

F1 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant.

SEC source: 0001933414-25-000010 · wk-form4_1739485768.xml · derivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,229

Underlying: Common Stock · 6,348 shares

Expires 2032-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-25-000010 · wk-form4_1739485768.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,520

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-25-000005 · wk-form4_1736995563.xml · nonDerivative · entry 2

Levy Adam Scott · CIK 0001693134 · CFO and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 226,097

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023.

SEC source: 0001933414-25-000005 · wk-form4_1736995563.xml · nonDerivative · entry 1

Levy Adam Scott · CIK 0001693134 · CFO and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 226,197

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.60 to $9.52. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001933414-25-000004 · wk-form4_1736995524.xml · derivative · entry 4

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,577

Underlying: Common Stock · 6,349 shares

Expires 2032-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-25-000004 · wk-form4_1736995524.xml · derivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,018 shares

Expires 2031-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-25-000004 · wk-form4_1736995524.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,172

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-25-000004 · wk-form4_1736995524.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 151,823

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This balance includes 797 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.

SEC source: 0001933414-25-000003 · wk-form4_1736995487.xml · nonDerivative · entry 1

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 877,608

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2024.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.65 to $9.37. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001933414-24-000062 · wk-form4_1734125816.xml · derivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,018

Underlying: Common Stock · 5,017 shares

Expires 2031-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.